Katz Considers the Role of Neoadjuvant Chemoradiation in Borderline Resectable Pancreatic Cancer
Season 7, Episode 22, Aug 11, 2022, 08:55 PM
Dr Katz discusses the implications of a recently published phase 2 study investigating neoadjuvant mFOLFIRINOX with or without hypofractionated radiation therapy results for patients with borderline resectable pancreatic ductal adenocarcinoma.